Oncopeptides soon will seek conditional approval of melflufen (melphalan flufenamide) in the EU for the treatment of relapsed or refractory multiple myeloma. The pharmaceutical…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
After first rejecting a Sarclisa (isatuximab) triple combination therapy due to cost-effectiveness concerns, the U.K.’s National Institute for Health and Care…
NexImmune has dosed the first patient participating in its Phase 1/2 trial of NEXI-002, the company’s investigational T-cell therapy for multiple…
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to oNKord, Glycostem Therapeutics‘ cell-based therapy for the…
A recent collaboration between Cytovia Therapeutics and Inserm, the French National Institute of Health and Medical Research, aims to advance new immunotherapies against…
The National Cancer Institute (NCI) has awarded $1.7 million to support the work of a University of Arkansas for Medical…
